TIS tissue therapies limited

The problem with the lack of detail is that the market wants to...

  1. 2,243 Posts.
    lightbulb Created with Sketch. 109
    The problem with the lack of detail is that the market wants to know how TIS plans to get from A to B. What will TIS's responsibilities be? Also when we get to B, what will it mean?
    Without knowing any of this, we have no idea about what risks we face or the return on those risks. Not having any idea of those risks is itself a huge risk. Does it mean that there is no plan? If there is, then why not tell shareholders for god's sake...
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.